Wells Fargo lowered the firm’s price target on Danaher (DHR) to $205 from $210 and keeps an Equal Weight rating on the shares. The firm notes the company posted a solid beat/raise on EPS, while also leaving another about +15c-20c in its back pocket. Bioprocess continues to show a solid recovery, while LS should improve in the second half of the year. Pharma and China commentary was positive, Wells adds, arguing that CFO transition seems manageable.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Balanced Outlook for Danaher: Solid Earnings Beat Amidst Cautious Guidance and Mixed Segment Performance
- Danaher: Strong Q2 Performance and Growth Potential Justify Buy Rating
- Danaher Corporation Reports Steady Q2 2025 Earnings
- Danaher Earnings Call: Balancing Growth and Challenges
- Danaher’s Growth Potential and Strategic Positioning Justify Buy Rating